Pharsight

Lo Loestrin Fe patents expiration

LO LOESTRIN FE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984 APIL Extended estrogen dosing contraceptive regimen
Feb, 2029

(5 years from now)

Lo Loestrin Fe is owned by Apil.

Lo Loestrin Fe contains Ethinyl Estradiol; Norethindrone Acetate.

Lo Loestrin Fe has a total of 1 drug patent out of which 0 drug patents have expired.

Lo Loestrin Fe was authorised for market use on 21 October, 2010.

Lo Loestrin Fe is available in tablet;oral dosage forms.

Lo Loestrin Fe can be used as lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

The generics of Lo Loestrin Fe are possible to be released after 02 February, 2029.

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Market Authorisation Date: 21 October, 2010

Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

How can I launch a generic of LO LOESTRIN FE before it's drug patent expiration?
More Information on Dosage

LO LOESTRIN FE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic